Brain Histamine N-Methyltransferase as a Possible Target of Treatment for Methamphetamine Overdose
Author(s) -
Junichi Kitanaka,
Nobue Kitanaka,
F. Scott Hall,
George R. Uhl,
Motohiko Takemura
Publication year - 2016
Publication title -
drug target insights
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 12
ISSN - 1177-3928
DOI - 10.4137/dti.s38342
Subject(s) - meth , methamphetamine , histamine , medicine , pharmacology , histamine n methyltransferase , histamine h2 receptor , chemistry , receptor , monomer , organic chemistry , acrylate , antagonist , polymer
Stereotypical behaviors induced by methamphetamine (METH) overdose are one of the overt symptoms of METH abuse, which can be easily assessed in animal models. Currently, there is no successful treatment for METH overdose. There is increasing evidence that elevated levels of brain histamine can attenuate METH-induced behavioral abnormalities, which might therefore constitute a novel therapeutic treatment for METH abuse and METH overdose. In mammals, histamine N-methyltransferase (HMT) is the sole enzyme responsible for degrading histamine in the brain. Metoprine, one of the most potent HMT inhibitors, can cross the blood-brain barrier and increase brain histamine levels by inhibiting HMT. Consequently, this compound can be a candidate for a prototype of drugs for the treatment of METH overdose.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom